A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
The risks of major congenital malformations (MCMs) are not increased by first trimester tetracycline exposure, according to a recent study published in JAMA Network Open.1
Bacterial infections are often managed using tetracycline antibiotics, with use during pregnancy most common during the first trimester. However, tetracyclines are not recommended during pregnancy because of evidence indicating inhibition of skeletal development, dental hypoplasia, and irreversible discoloration.2
The current evidence against tetracyclines is from an older generation and based on use later in pregnancy. Therefore, updated data is needed about the safety of tetracycline use during pregnancy.1
To determine the association between first trimester tetracycline exposure and MCMs risk, investigators conducted a population-based cohort study. Singleton births from July 1, 2006, to December 31, 2018, in Sweden were selected from the Medical Birth Register.
Exclusion criteria included missing gestational age at birth, known teratogens exposure during the first trimester, mothers not residing in Sweden during the 1-year period before pregnancy and until birth, or not residing in Sweden in the first year of life. Data about drug prescription fills was obtained from the Prescribed Drug Register.
Investigators defined first trimester exposure as “having had at least 1 prescription filled by the mother between the first day of the last menstrual period and 97 days of gestation.” Gestational age was measured through ultrasonography at approximately 18 weeks’ gestation.
Unexposed infants were those born to mothers without any tetracycline prescription fills during the first trimester. The presence of any MCM within the first year of life was reported as the primary outcome, determined using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision Swedish diagnostic codes.
All infants were observed during a 1-year follow-up period. Secondary outcomes included all European Surveillance of Congenital Anomalies MCM organ system subgroups.
There were 1,245,889 infants included in the source cohort, with first trimester tetracycline exposure reported in 0.5%. These infants were more often born in earlier calendar years and had mothers who were in the youngest and oldest age strata, Swedish-born, with a lower education level, smoked during pregnancy, and used prescription drugs.
The analytical cohort included 69,656 infants, 6340 of whom were exposed to tetracyclines and 63,316 were unexposed. Of tetracycline-exposed infants, 39.75 per 1000 presented with any MCMs, vs 38.76 per 1000 infants in the unexposed cohort. This indicated no increased risk of any MCM between groups, with a relative risk (RR) of 1.03.
Of 12 MCM subgroups, 10 had no increased risk from tetracycline exposure. However, increased risks were reported for nervous system anomalies and eye anomalies, with RRs of 1.92 and 1.76, respectively. In the sensitivity analyses, these RRs were 2.64 and 1.35, respectively.
During the 3-year follow-up period, infants exposed to tetracyclines had a 1.6-fold increased risk of nervous system anomalies vs unexposed infants. Similarly, a 1.5-fold increased risk of eye anomalies was reported in these individuals.
When analyzing risk based on tetracycline type, the RRs for any MCM compared with unexposed infants were 1.07 for doxycycline only, 0.83 for lymecycline only, and 0.78 for tetracycline or oxytetracycline only. Increased rates of comorbidities, health care use, and drug use were reported in patients with short-term tetracycline use vs long-term use.
These results indicated no increased risks of MCMs from first trimester tetracycline exposure. Investigators recommended additional research to rule out potential risks.
References
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
Prenatal cannabis use not linked to offspring ASD development
November 1st 2024In a recent study, adjustments for maternal characteristics mediated the association between maternal prenatal cannabis use and offspring autism spectrum disorder, indicating no statistically significant increase in risk.
Read More
Importance of reproductive health services for adolescents during the COVID-19 pandemic
October 30th 2024In a recent study, high rates of reproductive health service use were reported among adolescent mothers, indicating the benefits of this model for providing care when other options are unavailable.
Read More